Sort
10,766 grants matching “checkpoint inhibitor”
Biomarkers for acute interstitial nephritis in humans
$632,009Dennis G. Moledina · Yale University · R01 · FY2021 · DK
The Genetics of Ocular Melanoma
$632,004Anne Mary Bowcock · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers
$631,958Cristian T Badea · Duke University · U24 · FY2018 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells
$631,907Mehmet Toner · Massachusetts General Hospital · R01 · FY2022 · CA
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
$631,885Javid J Moslehi · University Of California, San Francisco · R01 · FY2022 · HL
Inhibiting Multi-Functional ALDOA for Cancer Therapy
$631,803Garth Powis · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2020 · CA
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
$631,711Gregory R J Thatcher · University Of Arizona · R01 · FY2025 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$631,336Arvin Dar · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
$630,790Jennifer D Wu · Northwestern University At Chicago · R01 · FY2024 · CA
Engineered Lipid Nanoparticles and Microgel Matrix to Program Th1/Th2 Immune Response
$630,781Hai-Quan Mao · Johns Hopkins University · R01 · FY2025 · CA
The Genetics of Ocular Melanoma
$630,776Anne Mary Bowcock · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$630,691Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2023 · CA
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
$630,641Katherine W Ferrara · Stanford University · R01 · FY2019 · CA
NF-kappaB in pathogenesis and therapy of head and neck cancer
$630,635Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2016 · DC
Targeting polo-like kinase for therapy of small cell lung cancer
$630,466Taofeek K Owonikoko · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$630,404Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
The NOTCH Signaling Pathway in Large Vessel Vasculitis
$630,400Cornelia M Weyand · Mayo Clinic Rochester · R01 · FY2025 · HL
ER stress-driven IRE1a-XBP1 signaling in lung cancer
$630,307Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay
$630,231Yun Wu · State University Of New York At Buffalo · R01 · FY2023 · CA
Targeting STAT3 to enhance anti-tumor immunity
$630,039Daniel E Johnson · University Of California, San Francisco · R01 · FY2022 · DE
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment
$630,037Christine Anne Pratilas · Johns Hopkins University · R01 · FY2025 · CA
Clinical Studies in Pediatric Solid Tumors
$630,023Lee J. Helman · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors
$629,966Albert Folch · University Of Washington · R01 · FY2024 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$629,761Rebecca L Aft · Washington University · R01 · FY2021 · CA
Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi)
$629,751Cielito C Reyes-Gibby · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA